Trial Testing Psilocybin in Parkinson’s Nears End

A clinical trial testing the impact of low doses of psilocybin, a naturally occurring psychedelic compound, on inflammatory activity in people with Parkinson’s disease is on track to be completed by the end of February. Sponsored by Silo Pharma and conducted at the Clinical & Translational Science Institute (CTSI)…